Stock Scorer

Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals Inc. reported revenue of 17.9M USD for the quarter ending 30 June 2026, up 85.2% from 9.7M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 17.9M +85.2%
Gross Profit Q4 '23 · ending 31 December 2023 9.1M —
Operating Income Q2 '26 · ending 30 June 2026 1.7M —
Net Income Q2 '26 · ending 30 June 2026 2M —
Cost of Revenue Q4 '23 · ending 31 December 2023 685K —
Operating Cash Flow Q2 '26 · ending 30 June 2026 50K —
Free Cash Flow Q3 '14 · ending 30 September 2014 -443K —
Shares Outstanding Q2 '26 · ending 30 June 2026 36.4M +32.1%
EPS Q2 '26 · ending 30 June 2026 -0.12 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 44.6M-6.3M-9.7M—
20242024-12-31 47.5M2.6M-436K—
20232023-12-31 21.3M-12.8M-16M—
20222022-12-31 1.5M-22.6M-23.7M—
20202020-12-31 170K-17.9M-18.1M—
20192019-12-31 0-13M-12.8M—
20182018-12-31 0-10.4M-9.9M—
20172017-12-31 0-7M-7M—
20162016-12-31 0-2.9M-2.8M—

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-3017.9M
Q1 '262026-03-3115.1M
Q4 '252025-12-3113.8M
Q3 '252025-09-3012.5M
Q2 '252025-06-309.7M
Q1 '252025-03-318.8M
Q4 '242024-12-317.9M
Q3 '242024-09-307M
Q2 '242024-06-307.3M
Q1 '242024-03-3125.4M
Q4 '232023-12-3110M
Q3 '232023-09-306.5M
Q2 '232023-06-303.3M
Q1 '232023-03-311.7M
Q1 '212021-03-310
Q4 '202020-12-31170K
Q3 '202020-09-300
Q2 '202020-06-300
Q1 '202020-03-310
Q4 '192019-12-310

Gross Profit Quarterly

PeriodEndingGross Profit
Q4 '232023-12-319.1M
Q3 '232023-09-306.2M
Q2 '232023-06-303.2M
Q1 '232023-03-311.6M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-301.7M
Q1 '262026-03-31-119K
Q4 '252025-12-31-2.6M
Q3 '252025-09-30-189K
Q2 '252025-06-30-2.7M
Q1 '252025-03-31-808K
Q4 '242024-12-31-934K
Q3 '242024-09-30-5.2M
Q2 '242024-06-30-5M
Q1 '242024-03-3113.7M
Q4 '232023-12-31-1.8M
Q3 '232023-09-30-1M
Q2 '232023-06-30-4.7M
Q1 '232023-03-31-5.3M
Q4 '222022-12-31-6.1M
Q3 '222022-09-30-7.9M
Q2 '222022-06-30-5M
Q1 '222022-03-31-3.5M
Q4 '212021-12-31-4.2M
Q3 '212021-09-30-4.2M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-302M
Q1 '262026-03-31201K
Q4 '252025-12-31-4.8M
Q3 '252025-09-30-638K
Q2 '252025-06-30-3.2M
Q1 '252025-03-31-1.2M
Q4 '242024-12-31-2M
Q3 '242024-09-30-5.7M
Q2 '242024-06-30-5.6M
Q1 '242024-03-3112.8M
Q4 '232023-12-31-28.5M
Q3 '232023-09-30-1.9M
Q2 '232023-06-30-5.4M
Q1 '232023-03-31-6.1M
Q4 '222022-12-31-6.9M
Q3 '222022-09-30-8.1M
Q2 '222022-06-30-5.1M
Q1 '222022-03-31-3.7M
Q4 '212021-12-31-4.4M
Q3 '212021-09-30-4.2M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q4 '232023-12-31685K
Q3 '232023-09-30331K
Q2 '232023-06-30148K
Q1 '232023-03-3195K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-3050K
Q1 '262026-03-312.4M
Q4 '252025-12-31-6M
Q3 '252025-09-301.5M
Q2 '252025-06-30-3.7M
Q1 '252025-03-31-4.3M
Q4 '242024-12-31-1.5M
Q3 '242024-09-30-2.2M
Q2 '242024-06-30-8.4M
Q1 '242024-03-3139M
Q4 '232023-12-31-4.9M
Q3 '232023-09-30-2.8M
Q2 '232023-06-30-3.9M
Q1 '232023-03-31-5.6M
Q4 '222022-12-31-6.8M
Q3 '222022-09-30-5M
Q2 '222022-06-30-3.4M
Q1 '222022-03-31-2.9M
Q4 '212021-12-31-3.2M
Q3 '212021-09-30-3M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q3 '142014-09-30-443K
Q2 '142014-06-30-410K
Q1 '142014-03-31-378K
Q4 '132013-12-31-445K
Q3 '132013-09-30-469K
Q2 '132013-06-30-889K
Q1 '132013-03-31-407K
Q4 '122012-12-31-557K
Q3 '122012-09-30-726K
Q2 '122012-06-30-1.1M
Q1 '122012-03-31-578K
Q4 '112011-12-31-767K
Q3 '112011-09-30-636K
Q2 '112011-06-301.8M
Q1 '112011-03-31-1M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-3036.4M
Q1 '262026-03-3135.5M
Q3 '252025-09-3027.9M
Q2 '252025-06-3027.7M
Q1 '252025-03-3127.6M
Q3 '242024-09-3027.4M
Q2 '242024-06-3027.3M
Q1 '242024-03-3131.1M
Q3 '232023-09-3026.6M
Q2 '232023-06-3026.5M
Q1 '232023-03-3126.6M
Q3 '222022-09-3026.1M
Q2 '222022-06-3026.1M
Q1 '222022-03-3126M
Q3 '212021-09-3026M
Q2 '212021-06-3026M
Q1 '212021-03-3126M
Q3 '202020-09-3025.6M
Q2 '202020-06-3023.4M
Q1 '202020-03-3119.9M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.12
Q1 '262026-03-31-0.28
Q4 '252025-12-31-0.33
Q3 '252025-09-30-0.19
Q2 '252025-06-30-0.38
Q1 '252025-03-31-0.47
Q4 '242024-12-31-0.02
Q3 '242024-09-30-0.13
Q2 '242024-06-300.01
Q1 '242024-03-31-0.00
Q4 '232023-12-31-0.64
Q3 '232023-09-30-0.76
Q2 '232023-06-30-1.00
Q1 '232023-03-31-0.98
Q4 '222022-12-31-0.89
Q3 '222022-09-30-0.81
Q2 '222022-06-30-0.66
Q1 '222022-03-31-0.62
Q4 '212021-12-31-0.66
Q3 '212021-09-30-0.61